<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165798</url>
  </required_header>
  <id_info>
    <org_study_id>3475-U01</org_study_id>
    <secondary_id>MK-3475-U01</secondary_id>
    <secondary_id>KEYMAKER-U01</secondary_id>
    <nct_id>NCT04165798</nct_id>
  </id_info>
  <brief_title>KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)</brief_title>
  <official_title>KEYMAKER-U01 Master Study: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is referred to as the &quot;umbrella master protocol&quot; for pembrolizumab (MK-3475) in&#xD;
      the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master&#xD;
      protocol uses a platform design and consists of this master screening study and three&#xD;
      substudies. Each substudy will enroll a different population of NSCLC participants.&#xD;
&#xD;
      The goal of this umbrella master protocol is to screen potential participants with NSCLC for&#xD;
      enrollment into 1 of 3 substudies. Participants must first enroll in this pembrolizumab&#xD;
      master protocol study and undergo screening for NSCLC that will be used to assign them to&#xD;
      participation in 1 of 3 pembrolizumab substudies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following 3 pembrolizumab substudies will evaluate the efficacy of different&#xD;
      investigational agents in combination with pembrolizumab given in sequence or in combination&#xD;
      with pembrolizumab PLUS chemotherapy:&#xD;
&#xD;
        -  KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational&#xD;
           Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naïve Patients&#xD;
           with Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A) - NCT04165070&#xD;
&#xD;
        -  KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational&#xD;
           Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive&#xD;
           Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B) - NCT04165083&#xD;
&#xD;
        -  KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational&#xD;
           Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung&#xD;
           Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy (MK-3475-01C) - NCT04165096&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">February 13, 2032</completion_date>
  <primary_completion_date type="Anticipated">February 13, 2032</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Level: Tumor Proportion Score (TPS) &lt;1% vs. TPS =1%</measure>
    <time_frame>Up to approximately 1 month</time_frame>
    <description>Participants' tumors will be evaluated for their PD-L1 tumor expression level using archival tumor tissue samples or newly obtained tumor tissue. The percentage of participants who have a Tumor Proportion Score (TPS) &lt;1% vs. a TPS =1% will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Histology Status: Squamous Non-small Cell Lung Cancer (NSCLC) vs. Nonsquamous NSCLC</measure>
    <time_frame>Up to approximately 1 month</time_frame>
    <description>Participants' tumors will be evaluated for their tumor histology status as being either squamous vs. nonsquamous NSCLC using archival or newly obtained tumor tissue samples. The percentage of participants who have squamous vs. nonsquamous NSCLC will be presented.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Prospective NSCLC Participants</arm_group_label>
    <description>Male and female participants with histologically-confirmed diagnosis of squamous or nonsquamous NSCLC will be screened for participation in 1 of 3 pembrolizumab substudies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tumor Imaging</intervention_name>
    <description>Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.</description>
    <arm_group_label>Prospective NSCLC Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor Tissue Collection</intervention_name>
    <description>Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.</description>
    <arm_group_label>Prospective NSCLC Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Sample Collection</intervention_name>
    <description>Participants will have blood samples drawn for analysis of:&#xD;
genetics&#xD;
ribonucleic acid (RNA)&#xD;
serum biomarker&#xD;
plasma biomarker&#xD;
circulating tumor DNA (ctDNA)</description>
    <arm_group_label>Prospective NSCLC Participants</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      To identify novel biomarkers, biospecimens (i.e., blood components, tumor material) will be&#xD;
      collected to support analyses of cellular components (eg, protein, DNA, RNA, metabolites) and&#xD;
      other circulating molecules.&#xD;
&#xD;
      Investigations may include but are not limited to:&#xD;
&#xD;
      Germline (blood) genetic analyses (e.g. single nucleotide polymorphism [SNP] analyses, whole&#xD;
      exome sequencing, whole genome sequencing)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female participants with histologically-confirmed diagnosis of squamous or&#xD;
        nonsquamous NSCLC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has histologically- or cytologically-confirmed diagnosis of Stage IV squamous or&#xD;
             nonsquamous NSCLC&#xD;
&#xD;
          -  Participants with nonsquamous NSCLC who are not eligible for an approved targeted&#xD;
             therapy&#xD;
&#xD;
          -  Is able to to provide archival tumor tissue sample collected either within 5 years or&#xD;
             within the interval from completion of last treatment but before entering the&#xD;
             screening period or newly obtained core or excisional biopsy of a tumor lesion not&#xD;
             previously irradiated obtained within 90 days of treatment initiation&#xD;
&#xD;
          -  Has not received prior systemic treatment for their metastatic NSCLC&#xD;
&#xD;
          -  Is able to complete all screening procedures within the 35-day screening window&#xD;
&#xD;
          -  Has adequate organ function within 10 days of initiation of study treatment&#xD;
&#xD;
          -  Male participants must agree to use contraception and should refrain from donating&#xD;
             sperm during the treatment period and:&#xD;
&#xD;
          -  Substudy 1: for at least 120 days after the last dose of pembrolizumab and for at&#xD;
             least 180 days after the last dose of chemotherapy&#xD;
&#xD;
          -  Substudies 2 and 3: for at least 120 days after study treatments&#xD;
&#xD;
          -  Female participants must not be pregnant or breastfeeding, and at least 1 of the&#xD;
             following conditions apply:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP), OR&#xD;
&#xD;
               2. A WOCBP who agrees to use contraception during the treatment period and:&#xD;
&#xD;
          -  Substudy 1: for at least 120 days after the last dose of pembrolizumab and for at&#xD;
             least 180 days after the last dose of chemotherapy.&#xD;
&#xD;
          -  Substudies 2 and 3: for at least 120 days after study treatment&#xD;
&#xD;
             *Substudies 1 and 2 Only:&#xD;
&#xD;
          -  Has not received prior systemic treatment for their metastatic NSCLC&#xD;
&#xD;
             *Substudy 2 Only:&#xD;
&#xD;
          -  Has a programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%&#xD;
&#xD;
             *Substudy 3 Only:&#xD;
&#xD;
          -  Has progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb)&#xD;
             administered either as monotherapy, or in combination with other checkpoint inhibitors&#xD;
             or other therapies&#xD;
&#xD;
          -  Has progressive disease during/after platinum doublet chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of small cell lung cancer&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days before the first dose of study treatment&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 2 years&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has clinically significant cardiac disease, including unstable angina, acute&#xD;
             myocardial infarction within 6 months from Day 1 of study treatment administration, or&#xD;
             New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
          -  Has a known history of HIV infection&#xD;
&#xD;
          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection&#xD;
&#xD;
          -  Has had major surgery &lt;3 weeks before the first dose of study treatment&#xD;
&#xD;
          -  Is expected to require any other form of antineoplastic therapy while on study&#xD;
&#xD;
          -  Has received prior radiation therapy to the lung that is &gt;30 Gray (Gy) within 6 months&#xD;
             of the first dose of study treatment&#xD;
&#xD;
          -  Has received a live vaccine within 30 days before the first dose of study treatment.&#xD;
             Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is&#xD;
             allowed as long as they are messenger ribonucleic acid (mRNA) vaccines, adenoviral&#xD;
             vaccines, or inactivated vaccines. Investigational vaccines (ie, those not licensed or&#xD;
             approved for Emergency Use) are not allowed&#xD;
&#xD;
          -  Has received any prior immunotherapy and was discontinued from that treatment due to a&#xD;
             severe or worse immune-related adverse event (irAE)&#xD;
&#xD;
          -  Has had chemotherapy or biological cancer therapy within 4 weeks before the first dose&#xD;
             of study treatment or has not recovered to Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered&#xD;
             more than 4 weeks before the first dose of study treatment (including participants who&#xD;
             had previous immunomodulatory therapy with residual irAEs)&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks before the first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Previously had a severe hypersensitivity reaction to treatment with monoclonal&#xD;
             antibodies (including pembrolizumab) and/or any of their excipients&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of study treatment&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
&#xD;
             *Substudy 1 Only:&#xD;
&#xD;
          -  Has symptomatic ascites or pleural effusion (if receiving pemetrexed)&#xD;
&#xD;
          -  Has a history or current evidence of a gastrointestinal (GI) condition (e.g.&#xD;
             inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver&#xD;
             function or diseases that in the opinion of the investigator may significantly alter&#xD;
             the absorption or metabolism of oral medications&#xD;
&#xD;
          -  Is getting chemotherapy and has clinically active diverticulitis, intra-abdominal&#xD;
             abscess, GI obstruction, or peritoneal carcinomatosis&#xD;
&#xD;
          -  Has preexisting neuropathy that is moderate in intensity&#xD;
&#xD;
          -  Is unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDs), other than aspirin dose less than or equal to 1.3 gm/day for a 5-day period&#xD;
             (8-day period for long acting agents such as peroxicam), for participants who will&#xD;
             receive pemetrexed&#xD;
&#xD;
          -  Is unable or unwilling to take folic acid or vitamin B12 supplementation, for&#xD;
             participants who will receive pemetrexed&#xD;
&#xD;
          -  Has a known sensitivity to any component of carboplatin, paclitaxel, pemetrexed or any&#xD;
             of their excipients&#xD;
&#xD;
             *Substudies 1 and 2 Only:&#xD;
&#xD;
          -  Has received prior systemic cytotoxic chemotherapy or other targeted or biological&#xD;
             antineoplastic therapy for metastatic disease&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death-1 (PD-1),&#xD;
             anti-programmed cell death-ligand 1 (PD-L1), or anti-PD-L2 agent or prior therapy&#xD;
             targeting other immunoregulatory receptors or mechanisms&#xD;
&#xD;
             *Substudy 3 Only:&#xD;
&#xD;
          -  Has received prior therapy targeting other immuno-regulatory receptors or mechanisms,&#xD;
             not including anti-PD-(L)1 agents&#xD;
&#xD;
          -  Has participated in Substudies 1 or 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center ( Site 0001)</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-256-3425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope ( Site 0014)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>626-218-9200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco ( Site 0007)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-885-7820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University ( Site 0036)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-2223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Markey Cancer Center ( Site 0019)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-218-0131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Franklin Square Medical Center ( Site 0033)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-777-7364</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 0003)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute ( Site 0002)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-632-4767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-691-6971</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center ( Site 0016)</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>603-650-4428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>551-996-4725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0034)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>929-455-2428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic ( Site 0006)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-636-6888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center ( Site 0015)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-366-0233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania ( Site 0010)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-220-9703</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center ( Site 0009)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-792-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz ( Site 0062)</name>
      <address>
        <city>Gyor</city>
        <state>Gyor-Moson-Sopron</state>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3696418244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0061)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0072)</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286400795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Oncology ( Site 0076)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+ 97247776750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center ( Site 0075)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972587040620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 0071)</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>4428132</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297472414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0074)</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 0070)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235307096</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi ( Site 0173)</name>
      <address>
        <city>Florence</city>
        <state>Firenze</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393209225506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 0081)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82215883369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital ( Site 0080)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82022281004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0082)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82215993114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48502204953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L Hospitalet ( Site 0090)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34605431976</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 0091)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

